Gisele Dion - Sep 1, 2022 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ Milton H. Werner, Attorney-In-Fact
Stock symbol
IKT
Transactions as of
Sep 1, 2022
Transactions value $
$0
Form type
4
Date filed
9/6/2022, 05:08 PM
Previous filing
Jun 3, 2022
Next filing
Jun 16, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (right to buy) Award $0 +60K $0.00 60K Sep 1, 2022 Common Stock 60K $0.95 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shares vest 50% on each of the first two anniversaries of September 1, 2022.